By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mallinckrodt Pharmaceuticals 

675 McDonnell Boulevard

Hazelwood  Missouri  63042  U.S.A.
Phone: 314-654-2000 Fax: 314-654-5381


Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.




Founder: Emil Mallinckrodt

CEO: Mark Trudeau

CFO: Matthew Harbaugh


Please click here for Mallinckrodt job opportunities.


All Products

Key Statistics

Ownership: Subsidiary

Web Site: Mallinckrodt
Symbol: MNK

Medical Device


Advanced Magnetics, Inc.  GastroMARK in North America

Company News
Mallinckrodt (MNK) To Report Earnings Results For First Quarter Of Fiscal 2017 3/27/2017 9:18:17 AM
Mallinckrodt (MNK) Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million 3/20/2017 9:47:30 AM
Mallinckrodt (MNK) Board Expands Company's Share Repurchase Plan By $1.0 Billion; Company Announces Results Of 2017 Annual General Meeting 3/1/2017 10:33:48 AM
Mallinckrodt (MNK) Reports Transition Period Results And Announces 2017 Guidance 2/7/2017 10:06:03 AM
Mallinckrodt (MNK) Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million 1/30/2017 6:35:02 AM
Mallinckrodt (MNK) Unloads Intrathecal Therapy Biz for About $203 Million 1/30/2017 6:26:59 AM
Mallinckrodt (MNK) Release: Pharma And FTC Resolve Questcor Pharmaceuticals, Inc. (QCOR) Matter 1/19/2017 10:51:37 AM
Mallinckrodt (MNK) To Report Earnings Results For Transition Period Of Oct. 1, 2016, To Dec. 30, 2016, On Feb. 7, 2017 12/29/2016 11:54:40 AM
Mesoblast (MSB.AX) And Mallinckrodt (MNK) Enter Into Equity Purchase Agreement To Exclusively Negotiate Development And Commercialization Of Mesoblast's Cell Therapy Products For Chronic Low Back Pain And Acute Graft Versus Host Disease 12/27/2016 3:48:51 PM
Mallinckrodt (MNK) Release: Health Economic Data On OFIRMEV (Acetaminophen) Injection Presented At 28th Annual National Forum Of The Institute For Healthcare Improvement 12/7/2016 7:54:05 AM